Saturday 17 October 2026
Export CHRS’s income statement to Excel — free account
Coherus Oncology, Inc.
CHRS Healthcare Biotechnology
In the quarter to June 2026, revenue grew 39.5%, EPS fell 105.1%, free cash flow fell 33.2% and total debt rose 1.03%, each against the same quarter a year earlier.
1.00
0.07
−6.54%
Follow CHRS
Coherus Oncology, Inc. (CHRS) P/E ratio
Coherus Oncology, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 17.6× (February 2020) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 1.0× | (80.97%) |
| FY2024 | 5.1× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 9.4× | (33.23%) |
| FY2019 | 14.1× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 1.0× | 4.05% |
| Dec 2025 | 1.0× | (21.13%) |
| Sep 2025 | 1.2× | 161.80% |
| 37 more quarters | Free account |
Against its own ten years
Low 0.0×
High 17.6×
Ten-year median
0.0×
Current reading's percentile
79
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CMPX Compass Therapeutics, Inc. compare | n/m |
| ADAG Adagene Inc. Sponsored ADR compare | n/m |
| WHWK Whitehawk Therapeutics, Inc. compare | n/m |
| MDWD MediWound Ltd. compare | n/m |
| CHRS Coherus Oncology, Inc. | n/m |
| IPHA Innate Pharma S.A. Sponsored ADR compare | n/m |
| DTIL Precision BioSciences, Inc. compare | n/m |
| ORMP Oramed Pharmaceuticals Inc. compare | 1.0× |
| VRXA Veraxa Biotech AG compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)